



20 June 2025

ASX Announcement

Receipt of R&D Tax Incentive Rebate

Inhalerx Limited (ASX: IRX) ("**InhaleRx**" or the "**Company**") advises it has received a rebate of approximately \$402,000 relating to its FY2024 Research and Development Tax Incentive claim.

Funds received will be primarily utilised for working capital purposes, with the balance being applied to partial repayment of amounts drawn under its \$38.5 million funding facility with Clendon Biotech Capital Pty Ltd ("**Clendon**").

The Company also advises that, following reassessment by the Company's tax advisers, it has lodged an amended tax return for FY 2023, and is confident it will receive an additional \$88,000 once processed, with those additional funds also to be utilized for working capital purposes.

This announcement has been authorised for release by the Board of InhaleRx Limited.

For further information:

www.inhalerx.com.au

James Barrie, Company Secretary

Phone +61 3 8678 4091

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited is an Australian drug development company which is developing unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors.

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for IRX and the Company's shareholders. The first medical indications under investigation are Breakthrough Cancer Pain ("**BTcP**") and Panic Disorder ("**PD**"), both of which currently have limited safe and effective treatment options.

IRX holds an innovation patent and provisional patents for the nominated indications and the Company plans to continue to strengthen this position.